荷兰小细胞肺癌患者预防性颅脑照射的人群研究
该研究基于荷兰癌症登记数据,分析2010-2018年新诊断小细胞肺癌患者预防性颅脑照射(PCI)的使用趋势和决定因素,并通过问卷调查放疗医生实践。结果显示PCI使用率在2017-2018年显著下降,且与Takahashi试验发表及机构MRI能力相关,实践差异增大。
要点
- 2017-2018年PCI使用率较2010-2014年显著下降,广泛期和局限期均如此。
- Takahashi试验影响放疗医生PCI推荐,但机构MRI能力不足者更易否认其影响。
- PCI实践差异增大,凸显持续开展试验的重要性。
核心结论
- 荷兰广泛期和局限期小细胞肺癌患者的PCI使用率自2017年起显著下降。
- Takahashi试验可能是下降原因,且影响程度因机构MRI能力而异。
- PCI实践差异显著增加,强调持续试验的必要性。
研究设计与样本
- 基于荷兰癌症登记数据的全国性人群队列研究,纳入2010-2018年新诊断小细胞肺癌患者。
- 采用逻辑回归模型分析PCI频率变化及决定因素。
- 2020年对荷兰肺癌放疗医生进行在线问卷调查。
主要发现
- 10,264例合格患者中4,894例(47%)接受了PCI。
- 与2010-2014年相比,2017-2018年广泛期小细胞肺癌PCI使用显著下降(OR 0.68,95%CI 0.60-0.77),局限期亦下降(OR 0.56,95%CI 0.47-0.67)。
- 发病年份、年龄、体能状态和胸部放疗是PCI的独立决定因素。
- 41名调查参与者中,广泛期小细胞肺癌推荐PCI的比例为总是22%、有时71%、从不7%;局限期为总是54%、有时44%、从不2%。
- 63%的放疗医生确认Takahashi试验影响广泛期PCI推荐,25%确认影响局限期推荐;否认影响与机构MRI能力不足相关。
关键数值与推荐
- PCI使用率在2017-2018年广泛期小细胞肺癌OR 0.68(95%CI 0.60-0.77),局限期OR 0.56(95%CI 0.47-0.67),均较2010-2014年下降。
- 调查中广泛期小细胞肺癌PCI推荐:总是22%、有时71%、从不7%;局限期:总是54%、有时44%、从不2%。
临床怎么用
- 放疗医生应关注PCI在小细胞肺癌中的使用趋势及Takahashi试验的影响。
- 机构MRI能力可能影响PCI推荐决策,需结合影像监测条件个体化选择。
- 实践差异增大提示需参考持续试验结果以规范PCI应用。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Controversy has arisen regarding the benefit of prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC), particularly since the 2017 Takahashi trial publication that supports MRI surveillance in extensive-stage (ES-)SCLC. The primary aim of this study was to assess trends and determinants in PCI use over the years 2010-2018. A secondary aim was to determine contemporary practice considerations among radiation oncologists (ROs). METHODS: A nationwide population-based cohort study was conducted using the Netherlands Cancer Registry data on all newly diagnosed SCLC patients (2010-2018). The change in PCI frequency over the years and determinants for PCI were analyzed using logistic regression models. Second, an online survey was performed among Dutch lung cancer ROs in 2020. RESULTS: Among 10,264 eligible patients, 4,894 (47%) received PCI. Compared to 2010-2014, PCI use significantly decreased in 2017-2018 in ES-SCLC (OR 0.68, 95%CI 0.60-0.77) and LS-SCLC (OR 0.56, 95%CI 0.47-0.67). Incidence year, age, performance status, and thoracic radiotherapy were independent determinants for PCI. Among 41 survey participants, PCI was recommended always/sometimes/never by 22%/71%/7% in ES-SCLC and 54%/44%/2% in LS-SCLC. For ES-SCLC and LS-SCLC, 63% and 25% of ROs, respectively, confirmed influence of the Takahashi trial on PCI recommendations. Denial of such influence was associated with insufficient institutional MRI capacity. CONCLUSIONS: A significant declining trend of PCI use in both ES-SCLC and LS-SCLC was observed in The Netherlands since 2017. The Takahashi trial seems an explanation for this trend even in LS-SCLC, with differential influence of the trial depending on institutional MRI capacity. An alarming increase in practice variation regarding PCI was found which stresses the importance of ongoing trials.
引用
- Tomassen ML, Aarts MJ, Peters M, et al. Prophylactic cranial irradiation in patients with small cell lung cancer in The Netherlands: A population-based study. Clin Transl Radiat Oncol. 2021. PMID: 33665386. doi:10.1016/j.ctro.2021.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。